Travere Therapeutics announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $175M of its common stock. Jefferies, J.P. Morgan, BofA Securities and SVB Securities are acting as the joint book-running managers for the offering.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TVTX:
- Travere Therapeutics Announces Proposed Public Offering of Common Stock
- Travere Therapeutics reports Q4 EPS ($1.03), consensus ($1.07)
- Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
- Wells Fargo downgrades Cerevel on lack of catalysts until 2024
- Travere Therapeutics price target raised to $44 from $40 at Canaccord
